OCC
data caveat$244M—
Orthocell
Orthobiologics
CelGro collagen scaffold for nerve and tendon repair; NeuraGen and TenGlide product lines
Data HealthFiling4C overdue · Dec 202580d
No cash data on fileFigures from ASX filings · not financial advice
[ VITALS ]
Cash on Hand
—
Runway
—Market Cap
$244M
Burn Rate
—
Shares Outstanding
271M
Pipeline Assets
3
3M Price
OCC.ASX$0.900-7.2% 3M
Low $0.720High $1.080
Pipeline Assets (3)
TendinoGenTendon Repair (Autologous Tenocytes)
Phase 3CelGroTendon Repair
ApprovedRemplirPeripheral Nerve Repair (Trauma)
ApprovedDiscovery
Preclinical
Ph 1
Ph 1/2
Ph 2
Ph 2/3
Ph 3
NDA
Capital Raises & Buybacks
show_chart
No capital raise or buyback data
Director Options & Rights
Director
Outstanding
Ex. Price
Expiry
No option data entered yet
Competitive Landscape
17 competitor trialsPhase 2+ · Non-ASX
Tendon Repair13 active trials
7 Ph41 Ph31 Ph2/34 Ph2
Peripheral Nerve Repair (Trauma)4 active trials
1 Ph41 Ph32 Ph2
Competitor trials from ClinicalTrials.gov (Phase 2+ historical, Phase 3+ refreshed weekly, active/recruiting, non-ASX sponsors). Approved drugs from OpenFDA (NDA/BLA only). Updated weekly via fetch_competitors.py.
Catalysts (2)
CelGro US Revenue Milestone
UpcomingExpectedarrow_upwardHigh31 Dec 2026
TendinoGen Phase 3 Trial Data
UpcomingSpeculativearrow_upwardHigh30 June 2027
| Event | Type | Confidence | Impact | Date | Status |
|---|---|---|---|---|---|
| CelGro US Revenue Milestone OCC targeting US commercial revenue growth as primary near-term catalyst. CE-marked and FDA 510(k)-cleared. | commercial milestone | Expected | arrow_upwardHigh |
Delivery Consistency Index
Historical delivery and spending consistency — data is limited for recently added companies.
Track record will build as data accumulates — we need completed catalysts with original guidance dates, or at least two quarterly 4Cs, before scoring kicks in.